Mankind Pharma Collaborates with Lepra Society to Establish CDCC Centers for Leprosy Screening of 80,000 Individuals
Written by Arushi Sharma
Mankind Pharma, a leading Indian pharmaceutical company, has joined forces with the Lepra Society to launch a comprehensive program to combat leprosy. The initiative focuses on eradicating the disease, raising awareness, and providing treatment to those affected.
Mankind Pharma, a prominent pharmaceutical company in India, has unveiled a strategic partnership with the Lepra Society to embark on a comprehensive initiative aimed at combating, raising awareness about, and treating leprosy.
Operating under their Corporate Social Responsibility (CSR) arm, the company is dedicated to effecting meaningful change in regions grappling with leprosy. As part of this initiative, Mankind Pharma has set up five exclusive Comprehensive Disability Care Centers (CDCC) across various locations.
Strategically positioned in areas identified as high-impact regions, these CDCCs include the NTR District in Andhra Pradesh, Guru Gobind Hospital in Delhi, the Government Hospital in Chandarpur, Maharashtra, the Community Care Centre in Odisha's Koraput, and Nirmal District in Telangana.
These centers remain operational year-round, addressing a spectrum of issues related to leprosy and elephantiasis. Mankind Pharma aims to deliver crucial treatment and raise awareness through these centers, collaborating closely with the Lepra Society.
Sheetal Arora, CEO of Mankind Pharma, expressed his optimism about this initiative, remarking, “At Mankind Pharma, we are deeply committed to the welfare of communities in India. Our partnership with the Lepra Society marks a significant stride in our mission to eliminate leprosy and foster awareness. The CDCCs established in pivotal regions will play a pivotal role in offering treatment and support to individuals affected by leprosy. We anticipate that the targeted communities will benefit from this renewed emphasis on leprosy.”
Mankind Pharma will undertake an array of vital activities to combat leprosy and its socio-economic repercussions. Over 80,000 individuals will undergo comprehensive screening, complemented by extensive awareness programs meticulously designed to educate and enlighten communities.
Moreover, the initiative aims to provide treatment to more than 6,000 patients through the morbidity management and disability program, underscoring the commitment to holistic care. Additionally, over 10 reconstructive surgeries are scheduled to be performed, aimed at restoring normalcy for affected individuals.
Acknowledging the broader impact of leprosy, the initiative will extend socio-economic support to over 400 families, tackling the multifaceted challenges faced by communities. These concerted efforts underscore Mankind Pharma's dedication to making a tangible difference in the lives of those affected by leprosy.